# US 2010/0166701 A1 · Method for treating renal cell carcinoma using glycogenolysis inhibitors > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2010/0166701 A1 - Document ID: US20100166701A1 - Status: Published application - Kind: A1 - Application number: 12/394,038 - Filed: 2009-05-26 - Published: 2010-07-01 - Earliest claimed: 2008-03-06 - Inventors: Glendon John Parker - Web page: https://patentgrep.com/patent/US20100166701A1 ## CPC - A61K 31/70: Carbohydrates; Sugars; Derivatives thereof (sorbitol A61K31/047) - A61K 31/00: Medicinal preparations containing organic active ingredients - A61K 31/404: Indoles, e.g. pindolol - A61K 38/2013: {IL-2} - A61K 38/212: {IFN-alpha} - A61K 38/47: acting on glycosyl compounds (3.2), e.g. cellulases, lactases - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) ## Abstract Renal cell carcinoma (RCC) exhibits unpredictable behavior, high recurrence rate, insensitivity to Positron-Emission Tomography (PET), and poor response to existing cancer treatments such as chemotherapy. Inhibition of glycogenolysis can restrict RCC tumor growth and increase its susceptibility to other treatments, in particular, those that compromise access to nutrient, such as anti-angiogenenic compounds. This can also increase uptake of glucose derivatives and thus increase sensitivity of PET. Reduction of glycogen stores within RCC through treatment with iron-salts can also reduce tumor growth rate through reducing activation of the hypoxia pathway. Thus, synergistic treatment of RCC with glycogenolysis inhibitors or inhibitors of glycogenosis, and/or in combination with anti-angiogenic compounds, can increase sensitivity of tumor detection, slow tumor formation and/or metastasis. ## Claims ### Claim 1 A method of treating a subject with cancer, the method comprising: administering to the subject an effective amount of at least one agent that inhibits glycogenolysis in combination with at least one chemotherapeutic agent. ### Claim 2 (depends on 1) The method of claim 1, wherein the cancer is clear cell carcinoma. ### Claim 3 (depends on 2) The method of claim 2, wherein the clear cell carcinoma is renal cell carcinoma. ### Claim 4 (depends on 1) The method of claim 1, wherein the glycogenolysis inhibitor inhibits at least one of glycogen phosphorylase, lysosomal α-glucosidase and phosphoglucomutase. ### Claim 5 (depends on 3) The method of claim 3, wherein the glycogenolysis inhibitor is N-(n-Nonyl)deoxynojirimycin. ### Claim 6 (depends on 3) The method of claim 3, wherein the glycogenolysis inhibitor is CP-3616819. ### Claim 7 (depends on 1) The method of claim 1, wherein the chemotherapeutic agent is azide. ### Claim 8 (depends on 1) The method of claim 1, wherein the chemotherapeutic agent is an anti-angiogenic compound. ### Claim 9 (depends on 8) The method of claim 8, wherein the anti-angiogenic compound is a VEGF-receptor inhibitor. ### Claim 10 (depends on 9) The method of claim 9, wherein the VEGF-receptor inhibitor is SU-11248. ### Claim 11 (depends on 1) The method of claim 1, wherein the chemotherapeutic agent is at least one of interleukin-2 and interferon-α. ### Claim 12 (depends on 1) The method of claim 1, wherein the glycogenolysis inhibitor decreases cellular metabolism, thereby increasing effectiveness of the chemotherapeutic agent. ### Claim 13 A method of treating an individual having clear cell carcinoma, the method comprising: administering to the individual an effective amount of at least one agent that inhibits glycogenolysis. ### Claim 14 (depends on 13) The method of claim 13, wherein the clear cell carcinoma is renal cell carcinoma. ### Claim 15 (depends on 13) The method of claim 13, wherein the glycogenolysis inhibitor inhibits at least one of glycogen phosphorylase, lysosomal α-glucosidase and phosphoglucomutase. ### Claim 16 (depends on 13) The method of claim 13, wherein the glycogenolysis inhibitor is N-(n-Nonyl)deoxynojirimycin. ### Claim 17 (depends on 13) The method of claim 13, wherein the glycogenolysis inhibitor is CP-3616819. ### Claim 18 A method of diagnosing and monitoring renal cell carcinoma in an individual comprising: obtaining a sample from the individual; measuring in the sample a level of at least one protein involved in cellular metabolism; and determining a presence or an increased metastatic potential of clear cell carcinoma based on the level of the at least one protein involved in cellular metabolism. ### Claim 19 (depends on 16) The method of claim 16, wherein the at least one protein is an enzyme involved in anaerobic non-oxidative glucose metabolism. ### Claim 20 (depends on 17) The method of claim 17, wherein the enzyme involved in anaerobic non-oxidative glucose metabolism is up-regulated indicating the presence or the increased metastatic potential renal cell carcinoma. ### Claim 21 (depends on 16) The method of claim 16, wherein the at least one protein is an enzyme involved in oxidative metabolism. ### Claim 22 (depends on 19) The method of claim 19, wherein the enzyme involved in oxidative metabolism is down-regulated indicating the presence or increased metastatic potential of renal cell carcinoma. ### Claim 23 A method of detecting cancer in a subject, the method comprising: administering to the subject an inhibitor of glycogenolysis; then administering to the subject a glucose-based composition; then monitoring uptake of the glucose-based composition by the cancer, thereby detecting the cancer. ### Claim 24 (depends on 23) The method of claim 23, wherein the cancer is clear cell carcinoma. ### Claim 25 (depends on 24) The method of claim 24, wherein the cancer is renal cancer. ### Claim 26 (depends on 23) The method of claim 23, wherein the glucose-based composition is fluorodeoxyglucose. ### Claim 27 (depends on 23) The method of claim 23, wherein administering an inhibitor of glycogenolysis results in a 20% or more increase uptake of the glucose-based composition by the cancer cells. ### Claim 28 (depends on 23) The method of claim 23, wherein the uptake of the glucose-based composition is monitored by a PET scan.